Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.

× No keyword cloud information.

23 in total

Review 1. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors: James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal: J Am Coll Cardiol Date: 2004-06-02 Impact factor: 24.094

2. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.

Authors: Paul M Ridker; Nancy Cook
Journal: Circulation Date: 2004-03-29 Impact factor: 29.690

3. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors: P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245

4. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal: Lancet Date: 2003-04-05 Impact factor: 79.321

5. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors:
Journal: JAMA Date: 2002-12-18 Impact factor: 56.272

6. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.

Authors: Allen J Taylor; Steven M Kent; Patrick J Flaherty; Louis C Coyle; Thor T Markwood; Marina N Vernalis
Journal: Circulation Date: 2002-10-15 Impact factor: 29.690

7. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Authors: Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; Tim Crowe; William J Sasiela; John Tsai; John Orazem; Raymond D Magorien; Charles O'Shaughnessy; Peter Ganz
Journal: N Engl J Med Date: 2005-01-06 Impact factor: 91.245

8. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology.

Authors: G Sangiorgi; J A Rumberger; A Severson; W D Edwards; J Gregoire; L A Fitzpatrick; R S Schwartz
Journal: J Am Coll Cardiol Date: 1998-01 Impact factor: 24.094

9. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors: Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321

10. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors: Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal: JAMA Date: 2004-03-03 Impact factor: 56.272